Combining Ultrasound and Etanercept for a More Effective Treatment of PsA & PsO

Speciality: Rheumatology


Speaker:

Dr. U R K Rao | MD (Med) AIIMS, N. Delhi; FRCP, London, Consultant Rheumatologist Sri Deepti Rheumatology Centre

Dr. P D Rath | MD,FACR,FRCP(Edin),FRCP(Glasgow)FNIMS,FRCM,GCPR (AUS), DIPLOMA MSK Ultrasound(UCAM,SPAIN)DIRECTOR AND HEAD OF DEPARTMENT, RHEUMATOLOGYMax Super Specialty Hospital

DR. V. Anandan | MD[Derm] ,DCH, DNB[Paed], Sr. Consultant Dermatologist & Paediatrician Professor & HOD of DVL & Cosmetology, Govt. Stanley Medical College

Description:

A warm welcome to all the medical practitioners in this interesting session on understanding the role of ultrasound in psoriatic arthritis and the use of etanercept in psoriatic arthritis and plaque psoriasis. 

Psoriatic arthritis is a chronic inflammatory arthritic disease. The patients undergo severe pain with psoriatic arthritis. Being a rheumatic disease it needs proper attention to the inflammatory pathways or rather targeting inflammatory molecules which can alter the responses and help in getting a potential cure.

Moreover, plaque psoriasis is the most common type of psoriasis that causes dry, itchy, raised skin patches (plaques) covered with scales and usually appear on the elbows, knees, lower back, and scalp.

Immunological pathways play a crucial role in disease management, especially in the case of rheumatological disease. Managing psoriatic arthritis or plaque psoriasis can be done by using TNF inhibitors. 

Etanercept, a TNF-inhibiting drug, can be an advanced treatment option in managing psoriatic arthritis or plaque psoriasis. These are mostly used for people with different types of rheumatic diseases. 

Therefore, listen to the webinar, grab the knowledge that is shared, and follow HiDoc for more such exciting webinar sessions.
 


See More Webinars @ Hidoc Webinars




Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Remote monitoring can improve recovery from cancer surgery

2.

Intractable cancers may respond better to treatment when using new radiation and high-performance computing.

3.

A Win for AI in Cancer; 2025's Transformative Drugs; FDA Clarifies 'Underway' Trials

4.

Conditional EU Nod for Weekly Pill in Pediatric Glioma

5.

high response rate when using a bispecific antibody to treat R/R multiple myeloma.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot